Skip to main content

SEOM clinical guidelines for treatment of prostate cancer

Clinical and Translational Oncology volume 14, pages 520–527 (2012)Cite this article

Abstract

Prostate cancer (PC) is the most common cancer in men. Many patients have prolonged survival and die of other diseases, so treatment decisions are often influenced by age and coexisting comorbidities. The main procedure to diagnose PC is an ultrasound-guided core needle biopsy, which is indicated when a digital rectal examination (DRE) finds nodularity or when PSA is >10 ng/ml, but is also recommended with PSA between 4.0 and 10 ng/ml. Depending on age, PSA, Gleason score and characteristics of the tumour, treatment options for localised PC are active surveillance, radical prostatectomy and radiation therapy. Androgen deprivation treatment (ADT) should be added to radiotherapy for men with intermediate- or high-risk PC. ADT is the current standard first-line treatment for metastatic PC. Castration-resistant PC is a heterogeneous entity. Several treatments such as sipuleucel-T, docetaxel-based chemotherapy, radium 223, cabazitaxel or abiraterone plus prednisone, zoledronic and denosumab, are useful for this situation.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Ferlaya J, Parkinb DM, Steliarova-Fouche E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46:765–781

    Article  Google Scholar 

  2. http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence. Accessed October 2010

  3. Schröder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328

    PubMed  Article  Google Scholar 

  4. Andriole GL, Crawford ED, Grubb RL 3rd et al; PLCO Project Team (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310–1319

    PubMed  Article  CAS  Google Scholar 

  5. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29:1228

    PubMed  Article  Google Scholar 

  6. (2010) Prostate. In: Edge SB, Byrd DR, Compton CC et al (eds) AJCC cancer staging manual, 7th edn. Springer, New York, NY, pp 457–468

  7. Heidenreich A, Bolla M, Joniau S et al. Guidelines on prostate cancer [online]. Available: http://www.uroweb.org/gls/pdf/Prostate%20Cancer%202010%20June%2017th.pdf. Accessed May 2011

  8. D'Amico AV, Whittington R, Malkowicz SB et al (1999) Pretreatment nomogram for prostatespecific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 17:168–172

    PubMed  Google Scholar 

  9. N CCN Clinical Practice Guidelines in Oncology. Prostate Cancer (online). Available: http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf. Accessed November 2010

  10. Briganti A, Chun FK, Salonia A et al (2006) Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 98:788–793

    PubMed  Article  Google Scholar 

  11. Hu JC, Gu X, Lipsitz SR et al (2009) Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 302:1557–1564

    PubMed  Article  CAS  Google Scholar 

  12. Shelley A, Kumar BF, Wilt CG et al (2009) A systematic review and meta-analysis of randomized trials of neo-adjuvant hormone therapy for localized and locally advanced prostate carcinoma. Cancer Treat Rev 35:9–17

    PubMed  Article  CAS  Google Scholar 

  13. Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathologic T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol 181:956–962

    PubMed  Article  Google Scholar 

  14. Van der Kwast TH, Bolla M, Van Poppel H et al (2007) Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25:4178–4186

    PubMed  Article  Google Scholar 

  15. Messing EM, Manola J, Sarosdy M et al (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781–1788

    PubMed  Article  CAS  Google Scholar 

  16. Kupelian PA, Potters L, Khuntia D et al (2004) Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58: 25–33

    PubMed  Article  Google Scholar 

  17. Michalski JM, Roach M 3rd, Merrick G et al (2009) ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology: prostate. Int J Radiat Oncol Biol Phys 74:667–672

    PubMed  Article  Google Scholar 

  18. Kuban DA, Tucker SL, Dong L et al (2008) Longterm results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74

    PubMed  Article  Google Scholar 

  19. Zietman AL, DeSilvio ML, Slater JD et al (2005) Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294:1233–1239

    PubMed  Article  CAS  Google Scholar 

  20. Al-Mamgani A, van Putten W, Heemsbergen W et al (2008) Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72:980–988

    PubMed  Article  Google Scholar 

  21. Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results fromthe MRC RT01 randomised controlled trial. Lancet Oncol 8:475–487

    PubMed  Article  Google Scholar 

  22. Kwok Y, Yovino S (2010) Update on radiationbased therapies for prostate cancer. Curr Opin Oncol 22:257–262

    PubMed  Article  Google Scholar 

  23. Biagioli MC, Hoffe SE (2010) Emerging technologies in prostate cancer radiation therapy: improving the therapeutic window. Cancer Control 17:223–232

    PubMed  Google Scholar 

  24. Bolla M, de Reijke TM, Tienhoven GV et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527

    PubMed  Article  CAS  Google Scholar 

  25. Boccon-Gibod L, Djavan WB, Hammerer P et al (2004) Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 58:382–390

    PubMed  Article  CAS  Google Scholar 

  26. Roach M III, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys 65:965–974

    PubMed  Article  Google Scholar 

  27. Seidenfeld J, Samson DJ, Hasselblad V et al (2000) Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 132:566–577

    PubMed  CAS  Google Scholar 

  28. Klotz L, Boccon-Gibod L, Shore ND et al (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallelgroup phase III study in patients with prostate cancer. BJU Int 102:1531–1538

    PubMed  Article  CAS  Google Scholar 

  29. Moul JW (2009) Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer 115:3376–3378

    PubMed  Article  Google Scholar 

  30. Ryan CJ, Small EJ (2005) Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol 23:8225–8231

    PubMed  Article  CAS  Google Scholar 

  31. Shaw GL, Wilson P, Cuzick J et al (2007) International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 99: 1056–1065

    PubMed  Article  CAS  Google Scholar 

  32. Smith MR, Egerdie B, Hernández Toriz N et al for the Denosumab HALT Prostate Cancer Study Group (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–755

    PubMed  Article  CAS  Google Scholar 

  33. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159

    PubMed  Article  Google Scholar 

  34. Smith MR, Saad F, Coleman R et al (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379:39–46

    PubMed  Article  CAS  Google Scholar 

  35. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    PubMed  Article  CAS  Google Scholar 

  36. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422

    PubMed  Article  CAS  Google Scholar 

  37. Parker C, Heinrich D, O'sullivan JM et al (2011) Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer 47[Suppl 1]:LBA 1

    Google Scholar 

  38. de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005

    PubMed  Article  Google Scholar 

  39. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376:1147–1154

    PubMed  Article  Google Scholar 

  40. Scher HI, Fizazi K, Saad F et al for the AFFIRM Investigators (2012) Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol 30[Suppl 5]:LBA1

    Google Scholar 

  41. Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822

    PubMed  Article  CAS  Google Scholar 

  42. Climent MA, Piulats JM, Sanchez-Hernandez A et al (2012) Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol (in press)

    Google Scholar 

Download references

Author information

Affiliations

  1. Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, C/ Dr. Esquerdo, 46, ES-28009, Madrid, Spain

    José Ángel Arranz Arija

  2. Unidad de Oncología Médica, Hospital Universitario de Guadalajara, Guadalajara, Spain

    Javier Cassinello Espinosa

  3. Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain

    Miguel Ángel Climent Durán

  4. Servicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Fernando Rivera Herrero

Authors
  1. José Ángel Arranz Arija
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier Cassinello Espinosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miguel Ángel Climent Durán
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fernando Rivera Herrero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José Ángel Arranz Arija.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Arranz Arija, J.Á., Cassinello Espinosa, J., Climent Durán, M.Á. et al. SEOM clinical guidelines for treatment of prostate cancer. Clin Transl Oncol 14, 520–527 (2012). https://doi.org/10.1007/s12094-012-0835-x

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-012-0835-x

Keywords

  • Prostate cancer
  • Castration
  • Guidelines
  • Castration-resistant
  • Hormonotherapy
  • Chemotherapy